To investigate this resistance mechanism, Chen used specific CRISPR/Cas9-induced peptide-MHC-I screening process to identify potential therapeutic targets in an AML model, identifying three key MHC-I negative regulators, surface protein 6 (SUSD6), transmembrane protein 127 (TMEM127), and E3 ubiquitin ligase WWP2 [55]. The gene discussed is TMEM127; the disease is acute myeloid leukemia.